SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Theriva Biologics Q3 net loss narrows on lower R&D costs

Theriva Biologics Q3 net loss narrows on lower R&D costs Overview U.S. cancer therapeutics developer

BMEACNTXGANXTOVX

Related stories